154 related articles for article (PubMed ID: 8918563)
1. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy.
Kahaly G; Pitz S; Müller-Forell W; Hommel G
Clin Exp Immunol; 1996 Nov; 106(2):197-202. PubMed ID: 8918563
[TBL] [Abstract][Full Text] [Related]
2. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.
Kahaly GJ; Pitz S; Hommel G; Dittmar M
J Clin Endocrinol Metab; 2005 Sep; 90(9):5234-40. PubMed ID: 15998777
[TBL] [Abstract][Full Text] [Related]
3. High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy.
Antonelli A; Saracino A; Alberti B; Canapicchi R; Cartei F; Lepri A; Laddaga M; Baschieri L
Acta Endocrinol (Copenh); 1992 Jan; 126(1):13-23. PubMed ID: 1736548
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy.
Baschieri L; Antonelli A; Nardi S; Alberti B; Lepri A; Canapicchi R; Fallahi P
Thyroid; 1997 Aug; 7(4):579-85. PubMed ID: 9292946
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
Brauer VF; Scholz GH
Med Klin (Munich); 2004 Feb; 99(2):71-6. PubMed ID: 14963657
[TBL] [Abstract][Full Text] [Related]
7. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study.
Ng CM; Yuen HK; Choi KL; Chan MK; Yuen KT; Ng YW; Tiu SC
Hong Kong Med J; 2005 Oct; 11(5):322-30. PubMed ID: 16219950
[TBL] [Abstract][Full Text] [Related]
8. Serum immunoglobulin G4 levels and Graves' disease phenotype.
Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
10. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
11. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
[TBL] [Abstract][Full Text] [Related]
12. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy.
Khoo DH; Ho SC; Seah LL; Fong KS; Tai ES; Chee SP; Eng PH; Aw SE; Fok AC
Thyroid; 1999 Dec; 9(12):1175-80. PubMed ID: 10646655
[TBL] [Abstract][Full Text] [Related]
13. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
14. Intravenous methylprednisolone pulse therapy for Graves' ophthalmopathy.
Hiromatsu Y; Tanaka K; Sato M; Kuroki T; Nonaka K; Kojima K; Nishimura H; Nishida H; Kaise N
Endocr J; 1993 Feb; 40(1):63-72. PubMed ID: 7951498
[TBL] [Abstract][Full Text] [Related]
15. New immunomodulators in the treatment of Graves' ophthalmopathy.
Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to porcine eye muscle in patients with Graves' ophthalmopathy: identification of serum immunoglobulins directed against unique determinants by immunoblotting and enzyme-linked immunosorbent assay.
Ahmann A; Baker JR; Weetman AP; Wartofsky L; Nutman TB; Burman KD
J Clin Endocrinol Metab; 1987 Mar; 64(3):454-60. PubMed ID: 2434519
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of serum immunoglobulin G4 in glucocorticoid therapy of Graves' ophthalmopathy.
Li Y; Luo B; Zhang J; Zhou X; Shao S; Xu W; Yang Y; Yuan G
Clin Endocrinol (Oxf); 2021 Oct; 95(4):657-667. PubMed ID: 33938028
[TBL] [Abstract][Full Text] [Related]
18. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy.
Kung AW; Michon J; Tai KS; Chan FL
Thyroid; 1996 Oct; 6(5):381-4. PubMed ID: 8936659
[TBL] [Abstract][Full Text] [Related]
19. High-dose intravenous therapy with 7S immunoglobulins in autoimmune endocrine ophthalmopathy.
Seppel T; Schlaghecke R; Becker A; Engelbrecht V; Feldkamp J; Kornely E
Clin Exp Rheumatol; 1996; 14 Suppl 15():S109-14. PubMed ID: 8828957
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
